(Reuters) - The U.S. Food and Drug Administration's panel of outside experts said a clinical study of the drug, also known as mifamurtide, was unclear and difficult to interpret.
IDM Pharma is seeking FDA approval for Junovan, called Mepact in Europe, to treat the cancer after patients undergo surgery and chemotherapy.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment